Opendata, web and dolomites

HPV OncoPredict SIGNED

A Groundbreaking Stand-Alone Diagnostic Kit to Predict Human Papilloma Virus Infections Evolving into Cervical Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HPV OncoPredict project word cloud

Explore the words cloud of the HPV OncoPredict project. It provides you a very rough idea of what is the project "HPV OncoPredict" about.

innovative    leaders    cellular    device    undergo    315    benefit    people    hpv    preventable    cytology    patented    patients    infected    papillomavirus    viral    technologies    self    earlier    cc    clinician    feared    guidelines    screening    market    population    10    women    vaccination    250    performed    prevention    nucleic    oncopredict    opinion    detected    accurate    smears    ivd    young    recommended    starting    samples    despite    disease    strategies    disruptive    smear    detection    ahead    competitor    single    curable    stand    reliably    companies    human    causing    acids    feed    primary    diagnosis    tests    capacity    pap    collected    formed    persistent    infection    replace    overwhelming    cervical    hiantis    cancer    responsible    identification    annually    kills    diagnostic    million    biomarkers    risk    truly    oncogenic    treatment    manner    shape    frequently    triage    stratify    genotypes    alone    hrhpv    detecting    healthcare    huge    genefirst    subsequent    positive    patient   

Project "HPV OncoPredict" data sheet

The following table provides information about the project.

Coordinator
GENEFIRST LIMITED 

Organization address
address: BUILDING E5 CULHAM SCIENCE CENTRE
city: ABINGDON
postcode: OX14 3DB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.genefirst.com/hpv-oncopredict
 Total cost 2˙945˙000 €
 EC max contribution 2˙923˙061 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENEFIRST LIMITED UK (ABINGDON) coordinator 1˙700˙000.00
2    HIANTIS SRL IT (MILAN) participant 1˙223˙061.00

Map

 Project objective

Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early. Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology (Pap smear), it is feared that its use as a stand-alone test in CC screening would be responsible for over-diagnosis and over-treatment.

HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. With the use of novel viral biomarkers, HPV OncoPredict, starting from a single self- or clinician-collected cellular sample, will enable women to undergo both primary cervical screening and, if HPV-positive, subsequent triage. HPV OncoPredict will allow HPV testing to reliably replace Pap smears in cervical cancer prevention, as recently recommended by European guidelines, being based on a disruptive technology ahead of any competitor’s product and supported by key opinion leaders.

The HPV testing market is huge (€315 M) with around 100 million tests performed each year. The consortium formed by GeneFirst and Hiantis, both highly innovative companies with patented technologies, has the capacity to bring HPV OncoPredict to success. HPV OncoPredict will not only shape the manner in which we stratify women at risk of developing cervical cancer, but also provide an accurate and cost effective test of disease to benefit patients. More importantly, it will feed into how healthcare systems implement screening strategies to benefit patient pathways.

 Publications

year authors and title journal last update
List of publications.
2018 M. Arbyn, E. Peeters, I. Benoy, D. Vanden Broeck, J. Bogers, P. De Sutter, G. Donders, W. Tjalma, S. Weyers, K. Cuschieri, M. Poljak, J. Bonde, C. Cocuzza, F.H. Zhao, S. Van Keer, A. Vorsters
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
published pages: 52-56, ISSN: 1386-6532, DOI: 10.1016/j.jcv.2018.08.006
Journal of Clinical Virology 107 2019-11-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HPV ONCOPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HPV ONCOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More